In Vivo CRO Market Size, Share & Trends Analysis Report By Model Type (Rodent Based, Non-rodent Based), By Modality (Small Molecule, Large Molecule), By Indication, By GLP Type (Non GLP, GLP Toxicology), By Region, And Segment Forecasts, 2024 - 2030
- Report ID: GVR-1-68038-011-8
- Number of Pages: 257
- Format: Electronic (PDF)
- Historical Range: 2018 - 2023
- Industry: Healthcare
Market Segmentation
- In Vivo CRO Model Type Outlook (Revenue, USD Million, 2018 - 2030)
- Rodent Based
- Rat Models
- Mice Models
- Others
- Non-Rodent Based
- Rodent Based
- In Vivo CRO Modality Outlook (Revenue, USD Million, 2018 - 2030)
- Small Molecules
- Large Molecules
- Cell & Gene Therapy
- CAR T-Cell Therapies
- CAR-NK Cell Therapy
- TCR-T Cell Therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA Therapy
- Others
- Cell & Gene Therapy
- In Vivo CRO Indication Outlook (Revenue, USD Million, 2018 - 2030)
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic Model
- Patient Derived Xenograft
- Xenograft
- Others
- CNS Conditions
- Epilepsy
- Parkinson's Disease
- Huntington's Disease
- Stroke
- Muscular Dystrophy
- Alzheimer’s Disease
- Traumatic Brain Injury
- Amyotrophic Lateral Sclerosis (ALS)
- Spinal Muscular Atrophy
- Muscle Regeneration
- Other Neurodevelopment Disorders
- Diabetes
- Obesity
- Pain Management
- Chronic Pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid Arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome
- Others
- Others
- Oncology
- In Vivo CRO GLP Type Outlook (Revenue, USD Million, 2018 - 2030)
- GLP Toxicology
- Non GLP
- In Vivo CRO Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- North America In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- North America In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- North America In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- North America In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- U.S.
- U.S. In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- U.S. In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- U.S. In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- U.S. In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- U.S. In Vivo CRO Market, By Model Type
- Canada
- Canada In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Canada In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Canada In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Canada In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- Canada In Vivo CRO Market, By Model Type
- North America In Vivo CRO Market, By Model Type
- Europe
- Europe In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Europe In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Europe In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Europe In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- UK
- UK In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- UK In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- UK In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- UK In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- UK In Vivo CRO Market, By Model Type
- France
- France In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- France In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- France In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- France In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- France In Vivo CRO Market, By Model Type
- Italy
- Italy In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Italy In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Italy In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Italy In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- Italy In Vivo CRO Market, By Model Type
- Spain
- Spain In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Spain In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Spain In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Spain In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- Spain In Vivo CRO Market, By Model Type
- Denmark
- Denmark In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Denmark In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Denmark In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Denmark In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- Denmark In Vivo CRO Market, By Model Type
- Sweden
- Sweden In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Sweden In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Sweden In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Sweden In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- Sweden In Vivo CRO Market, By Model Type
- Norway
- Norway In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Norway In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Norway In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Norway In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- Norway In Vivo CRO Market, By Model Type
- Europe In Vivo CRO Market, By Model Type
- Asia Pacific
- Asia Pacific In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Asia Pacific In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Asia Pacific In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Asia Pacific In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- China
- China In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- China In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- China In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- China In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- China In Vivo CRO Market, By Model Type
- Japan
- Japan In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Japan In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Japan In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Japan In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- Japan In Vivo CRO Market, By Model Type
- India
- India In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- India In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- India In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- India In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- India In Vivo CRO Market, By Model Type
- Thailand
- Thailand In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Thailand In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Thailand In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Thailand In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- Thailand In Vivo CRO Market, By Model Type
- South Korea
- South Korea In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- South Korea In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- South Korea In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- South Korea In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- South Korea In Vivo CRO Market, By Model Type
- Australia
- Australia In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Australia In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Australia In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Australia In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- Australia In Vivo CRO Market, By Model Type
- Asia Pacific In Vivo CRO Market, By Model Type
- Latin America
- Latin America In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Latin America In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Latin America In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Latin America In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- Brazil
- Brazil In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- North America In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Brazil In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Brazil In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- Brazil In Vivo CRO Market, By Model Type
- Mexico
- Mexico In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Mexico In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Mexico In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Mexico In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- Mexico In Vivo CRO Market, By Model Type
- Argentina
- Argentina In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Argentina In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Argentina In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Argentina In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- Argentina In Vivo CRO Market, By Model Type
- Latin America In Vivo CRO Market, By Model Type
- Middle East and Africa
- Middle East and Africa In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Middle East and Africa In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Middle East and Africa In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Middle East and Africa In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- South Africa
- South Africa In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- South Africa In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- South Africa In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- South Africa In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- South Africa In Vivo CRO Market, By Model Type
- Saudi Arabia
- Saudi Arabia In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Saudi Arabia In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Saudi Arabia In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Saudi Arabia In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- Saudi Arabia In Vivo CRO Market, By Model Type
- UAE
- UAE In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- UAE In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- UAE In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- UAE In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- UAE In Vivo CRO Market, By Model Type
- Kuwait
- Kuwait In Vivo CRO Market, By Model Type
- Rodent based
- Rat models
- Mice models
- Others
- Non-rodent based
- Rodent based
- Kuwait In Vivo CRO Market, By Modality
- Small molecules
- Large molecules
- Cell & gene therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Other (Includes- TCR-NK, CARM, and TAC-T)
- RNA therapy
- Others
- Cell & gene therapy
- Kuwait In Vivo CRO Market, By Indication
- Oncology
- Blood cancer
- Solid tumor
- Syngeneic model
- Patient derived xenograft
- Xenograft
- Others
- CNS conditions
- Epilepsy
- Parkinson's disease
- Huntington's disease
- Stroke
- Muscular dystrophy
- Alzheimer’s disease
- Traumatic brain injury
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy
- Muscle regeneration
- Other neurodevelopment disorders
- Diabetes
- Obesity
- Pain management
- Chronic pain
- Acute Pain
- Autoimmune/inflammation conditions
- Rheumatoid arthritis
- Multiple sclerosis
- Osteoarthritis
- Irritable bowel syndrome
- Others
- Others
- Oncology
- Kuwait In Vivo CRO Market, By GLP Type
- GLP toxicology
- Non GLP
- Kuwait In Vivo CRO Market, By Model Type
- Middle East and Africa In Vivo CRO Market, By Model Type
- North America
In Vivo CRO Market Dynamics
Drivers: Changing Regulatory Landscape
Regulatory approval procedures are becoming more stringent & time-consuming, and market players aim to receive product approvals as the first attempt to gain a higher market share. Pharmaceutical and biotechnology companies have to manage continuous changes in regulatory requirements, which span different business activities and multiple geographies worldwide. Noncompliance with changing regulatory requirements may result in penalties and delays, which may lead to loss of revenue. A major regulatory change is a reduction in timelines. For instance, Brazil’s regulatory body ANVISA made it compulsory to issue a written opinion letter within 45 days of protocol submission, a written final opinion letter within 60 days for post-registration petitions, and a final opinion letter within 120 days for a request for new drug registration. Such changes across the regulatory observation process are anticipated to reduce the clinical trial timeline, thereby boosting the rate of clinical trials and simultaneously augmenting the growth of in vivo preclinical services.
Increase In Offshoring Drugs To Emerging Economies
Budget scrutiny in well-established economies, pricing pressure, as well as alterations in reimbursement schemes are few of the prime factors that are expected to surge the adoption of cost-containment measures by drug sponsors. This trend is predicted to boost pharmaceutical outsourcing to developing nations such as India and China. Few of the advantages offered by contract developers in emerging countries are as follows:
-
Export infrastructure
-
Artificially low currency value
-
Low-cost labor
-
Government incentives for local manufacturers, especially in China
Outsourcing development services including preclinical in vivo services to contract service providers in developing economies is predicted to boost the demand for quality assurance & regulatory affairs services, thus assisting to the growth of consulting services such as Quality Management Services (QMS) as well as regulatory compliance services. Stringent processes for FDA approval and changes in regulatory norms in the EU region are anticipated to make the approval process in Europe complex and are few of the prime factors contributing to the offshoring of drug companies to developing nations.
Restraint: Regulatory And Legal Compliance Issues In Outsourcing
Service providers in developing countries may not comply with newer regulations in the U.S and Europe, which would lead to compliance issues. As a result, drug sponsors in the U.S. and EU would prefer domestic service providers or in-house manufacturing facilities to combat the cost of compliance and remediation. However, with the increasing demand for quality products, contract development companies across the globe face issues pertaining to compliance with the latest regulatory standards and are required to contract with third parties that provide quality assurance services such as compliance, remediation, and QMS. Changes in regulations in Europe and the U.S. are thus expected to increase compliance issues while outsourcing services to contract service providers.
What Does This Report Include?
This section will provide insights into the contents included in this in vivo CRO market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.
In vivo CRO market qualitative analysis
-
Industry overview
-
Industry trends
-
Market drivers and restraints
-
Market size
-
Growth prospects
-
Porter’s analysis
-
PESTEL analysis
-
Key market opportunities prioritized
-
Competitive landscape
-
Company overview
-
Financial performance
-
Product benchmarking
-
Latest strategic developments
-
In vivo CRO market quantitative analysis
-
Market size, estimates, and forecast from 2018 to 2030
-
Market estimates and forecast for product segments up to 2030
-
Regional market size and forecast for product segments up to 2030
-
Market estimates and forecast for application segments up to 2030
-
Regional market size and forecast for application segments up to 2030
-
Company financial performance
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
